Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 7 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Mutation Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences
Cytarabine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2017

A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

Gojo, I. , Beumer, J. H. , Pratz, K. W. , McDevitt, M. A. , Baer, M. R. , Blackford, A. L. , Smith, B. D. , Gore, S. D. , Carraway, H. E. , Showel, M. M. , Levis, M. J. , Dezern, A. E. , Gladstone, D. E. , Ji, J. J. , Wang, L. , Kinders, R. J. , Pouquet, M. , Ali-Walbi, I. , Rudek, M. A. , Poh, W. & 5 others Herman, J. G., Karnitz, L. M., Kaufmann, S. H., Chen, A. & Karp, J. E. Feb 1 2017 In : Clinical Cancer Research. 23, 3, p. 697-706 10 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Methylation
Phosphorylation
Polymers
Poly Adenosine Diphosphate Ribose

A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia

Pratz, K. W., Rudek, M. A., Gojo, I., Litzow, M. R., McDevitt, M. A., Ji, J., Karnitz, L. M., Herman, J. G., Kinders, R. J., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M. M., Gladstone, D. E., Levis, M. J., Tsai, H. L., Rosner, G., Chen, A., Kaufmann, S. H. & Karp, J. E. Feb 15 2017 In : Clinical Cancer Research. 23, 4, p. 899-907 9 p.

Research output: Contribution to journalArticle

Leukemia, Myelomonocytic, Chronic
Topotecan
Carboplatin
Leukemia
Neoplasms

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Knapper, S., Russell, N., Gilkes, A., Hills, R. K., Gale, R. E., Cavenagh, J. D., Jones, G., Kjeldsen, L., Grunwald, M. R., Thomas, I., Konig, H., Levis, M. J. & Burnett, A. K. Mar 2 2017 In : Blood. 129, 9, p. 1143-1154 12 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Phosphotransferases
Drug Therapy
Database Management Systems

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide

Kayser, S. , Krzykalla, J. , Elliott, M. A. , Norsworthy, K. , Gonzales, P. , Hills, R. K. , Baer, M. R. , Ráčil, Z. , Mayer, J. , Novak, J. , Žák, P. , Szotkowski, T. , Grimwade, D. , Russell, N. H. , Walter, R. B. , Estey, E. H. , Westermann, J. , Görner, M. , Benner, A. , Krämer, A. & 10 others Smith, B. D., Burnett, A. K., Thiede, C., Röllig, C., Ho, A. D., Ehninger, G., Schlenk, R. F., Tallman, M. S., Levis, M. J. & Platzbecker, U. Apr 18 2017 In : Leukemia.

Research output: Contribution to journalArticle

Acute Promyelocytic Leukemia
Arsenic
Tretinoin
Recurrence
Acute Myeloid Leukemia
Graft vs Host Disease
Cyclophosphamide
Transplantation
Recurrence
Bone Marrow